Paul M D, Parfrey P, Marshall D, Aldrete V, Purchase L, Gault H
Nephron. 1986;44(2):96-102. doi: 10.1159/000183974.
The outcome and complications which developed in 8 hemodialysis patients who received 12 DiaTAP bioCarbon button vascular-access devices were reviewed. All patients had a poor vascular access history. Three of twelve devices have been replaced because of thrombosis and two because of infection. Four patients have had 10 episodes of reduced blood flow. Streptokinase infusion into the DiaTAP button led to improved blood flow in 8 of 10 episodes. The 6-month survival rate of the DiaTAP access device was 67% and the average functioning life was 9.4 months. It was a valuable form of access when others had failed.
对8例接受了12个DiaTAP生物碳纽扣式血管通路装置的血液透析患者所出现的结果及并发症进行了回顾。所有患者既往血管通路情况均较差。12个装置中有3个因血栓形成而被更换，2个因感染而被更换。4例患者出现了10次血流量减少的情况。向DiaTAP纽扣内注入链激酶后，10次中有8次血流量得到改善。DiaTAP血管通路装置的6个月生存率为67%，平均使用期限为9.4个月。当其他血管通路方式失败时，它是一种有价值的血管通路形式。
